Search Results

Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University Completes Its First PET/CT-Guided Interventional Puncture Procedure

From August 21 to 22, Professor Sun Long from the PET Center of the First Affiliated Hospital of Xiamen University was invited to the Department of Nuclear Medicine at the Affiliated Hospital of Southwest Medical University for academic exchange, and on the following day provided on-site guidance for the hospital's first PET/CT-guided interventional puncture procedure. The successful completion of this procedure marks a new clinical practice milestone for the department in the field of interventional nuclear medicine. On August 21, Professor Sun Long delivered a special lecture titled "Exploration of Clinical Integrated Application of Diagnostic Nuclear Medicine and Interventional Nuclear Medicine Based on the PET Platform," focusing on how the PET platform extends from disease diagnosis and precise localization to interventional diagnosis and treatment. Drawing on clinical practice and typical cases, he introduced the application of interventional nuclear medicine in lesion...

2026-08-27

UK's InHealth Deploys Europe's First Mobile Biograph Trinion PET/CT System

InHealth, a UK independent diagnostic service provider, has recently completed the first patient scan using Europe's first mobile Biograph Trinion PET/CT system. The system, supplied by Siemens Healthineers, is now in clinical use at Wrexham Maelor Hospital in northeast Wales to support cancer-related molecular imaging examinations. PET/CT is an important imaging technology in oncology diagnosis and treatment, applicable to the diagnosis, staging, treatment planning, and therapy response monitoring of various cancer types. Deploying the Biograph Trinion PET/CT system on a mobile platform means that advanced molecular imaging services can be delivered into clinical settings with greater flexibility, helping to improve patient access to...

2026-08-26

Cubresa Brain PET Scanner Receives FDA 510(k) Clearance, Integrates with Existing PET/MR Systems

Molecular imaging technology company Cubresa Inc. announced on August 20 that its Cubresa BrainPET™ scanner has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). According to the company, the Cubresa BrainPET™ is a positron emission tomography (PET) device specifically designed for brain imaging and can be integrated into existing Siemens Biograph mMR MR/PET systems. The device enables healthcare institutions to perform simultaneous PET/MR brain imaging on existing MRI infrastructure, capturing molecular and anatomical information without the need to purchase a separate whole-body hybrid imaging system. Cubresa founder and CEO James ...

2026-08-22

CFHI Dalian Nuclear Power Evaporator Clean Room Project Advances Preliminary Preparations

Recently, preliminary preparations are advancing for the clean room project under the evaporator batch manufacturing capacity building initiative of CFHI Dalian Nuclear Power & Petrochemical. Located in the Dalian Bay coastal equipment manufacturing cluster, the project will improve the clean operating conditions for nuclear power evaporator production and address the shortcomings in supporting processes for batch manufacturing. The project has a total investment of 18.81 million yuan, covering an area of approximately 2,600 square meters, with a new building area of approximately 2,600 square meters. The construction centers on the evaporator tube bundle assembly clean room, supplemented by installation workstations, channel head storage areas, packaging transport track systems, and air purification systems. Since the project launch, relevant departments in Dalian Bay have been providing service support for preliminary work including land planning, engineering scheme preparation, and approval coordination, while liaising with municipal and district-level industry authorities to resolve bottlenecks in project advancement and improve the efficiency of preliminary preparations.

2026-08-22

Global PET Market Expected to Reach $2.81 Billion by 2035, PET-CT Remains Dominant

A market research report shows that the global Positron Emission Tomography (PET) market size is expected to increase from $1.86 billion in 2025 to $2.81 billion by 2035, with a compound annual growth rate (CAGR) of 4.26% from 2026 to 2035. Increased demand for cancer diagnosis, expanded application of hybrid imaging technologies such as PET-CT and PET-MRI, and continued development of molecular imaging technologies are considered major factors driving market growth. The report notes that PET scans are being increasingly used in scenarios such as cancer detection and treatment evaluation, cardiac disease assessment, and diagnosis of neurological and psychiatric disorders. Meanwhile, population aging, rising healthcare expenditures, and growing demand for early screening are also driving...

2026-08-23

Norroy Bioscience's 68Ga-NYM096 Receives FDA Breakthrough Therapy and Fast Track Designations

China-based Norroy Bioscience announced on August 19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to its radiopharmaceutical imaging agent 68Ga-NYM096. The agent is a PET imaging tracer targeting carbonic anhydrase IX (CAIX), intended for imaging clear cell renal cell carcinoma (ccRCC). According to the company, 68Ga-NYM096 is being developed as a non-invasive PET imaging tool to characterize renal masses detected by CT or MRI and to help distinguish clear cell renal cell carcinoma from other non-ccRCC renal lesions. Clear cell renal cell carcinoma is the most common subtype of renal cell carcinoma...

2026-08-21

Vivos Ships First Batches from U.S. IsoPet Production Facility, Receives AERB Approval to Build International Manufacturing Center in India

KENNEWICK, Wash. — Vivos Inc. recently announced two operational milestones: its in-house production facility in Richland, Washington, has begun delivering IsoPet® products to certified veterinary clinics in the United States; simultaneously, the company has received authorization from India's Atomic Energy Regulatory Board (AERB) to establish an international manufacturing center in India. This means Vivos will have a two-site production footprint spanning the U.S. and India. According to the company, the U.S. production facility, housed at the Applied Process Engineering Laboratory (APEL), will manufacture IsoPet® veterinary oncology products and RadioGel® human oncology products, and will serve as the center for subsequent process improvements and regulatory...

2026-08-19

Decoding the Clinical-Radiological Paradox: Brain Network Mechanisms in Spinocerebellar Ataxia Type 3 Revealed

On August 17, the team of Professor Liu Chen and Professor Wang Jian from the Department of Radiology at Southwest Hospital of Army Medical University, in collaboration with Professor Long Zhiliang's team from the Faculty of Psychology at Southwest University, systematically revealed for the first time the micro-level molecular pathological mechanisms underlying macroscopic brain network decoupling in patients with spinocerebellar ataxia type 3 (SCA3) by integrating multimodal magnetic resonance imaging technology with high-resolution micro-biological atlases. This provides a novel perspective and objective imaging targets for resolving the clinical-radiological dissociation challenge in clinical diagnosis and treatment. The findings were published in the internationally leading journal in the field of movement disorders under the title "Putaminal Structure-Function Decoupling as an Early Candidate Imaging Biomarker for Motor Severity in Spinocerebellar Ataxia Type 3."

2026-08-18

FDG PET/CT Enables More Precise Identification of Multiorgan Involvement in Brazilian Paracoccidioidomycosis

A study conducted by researchers at the Brazilian CEPID CancerThera center shows that molecular imaging with fluorodeoxyglucose (FDG) PET/CT can detect systemic lesions of paracoccidioidomycosis (PCM) more sensitively than conventional staging methods, helping to reassess the extent and severity of the disease. The findings were published in Clinical Infectious Diseases. Paracoccidioidomycosis is a systemic fungal disease caused by inhalation of fungal spores of the Paracoccidioides genus, with significant clinical and epidemiological importance in Brazil. Often referred to as "coffee planter's disease," it primarily affects the lungs but can also spread to multiple organs via lymphatic and hematogenous routes. Conventional staging typically relies on...

2026-08-17

Korean Hospital Team Develops AI Model to Improve Bone Metastasis Detection Using PET/CT and Other Information

A research team at Seoul Metropolitan Government Seoul National University Boramae Medical Center has recently developed an artificial intelligence model capable of identifying bone metastases that are difficult to detect on CT images. By incorporating MRI and PET/CT information during the training process, the model enables lesions that are inconspicuous on CT and prone to being missed to be included in the training data, thereby enhancing detection capability. Bone metastasis is an important basis for determining cancer staging and formulating treatment plans. If lesions are not clearly visible on CT images, bone metastasis may be detected late and may lead to complications such as pathological fractures and spinal cord compression. Previous related AI studies have largely relied on lesions clearly visible on CT to build training data, and the research team believes that this approach may...

2026-08-17

FDA Approves Tauklarify, a Tau PET Imaging Agent for Alzheimer's Disease

The U.S. Food and Drug Administration has approved Tauklarify, a new brain imaging agent for the evaluation of Alzheimer's disease. The drug, also known as MK-6240, is a radioactive diagnostic agent for positron emission tomography (PET) in adults, primarily indicated for adults with cognitive impairment who require physician assessment of abnormal tau protein accumulation in the brain. The twisted, insoluble fibrous deposits formed by tau protein are believed to be associated with neurodegenerative diseases such as Alzheimer's disease. The developer, Lantheus, stated that the safety of Tauklarify was evaluated in two clinical trials involving more than 1,700 subjects. Adverse reactions...

2026-08-16

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

A research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK established a novel geometric imaging principle utilizing positron three-photon decay. Using a gamma-ray measurement system comprising scintillators and silicon photomultipliers (SiPMs), along with the existing PET radiopharmaceutical ^18F-FDG, they successfully visualized the positronium three-photon decay ratio for the first time, completing the proof-of-principle for Positronium Ratio Imaging (PRI). The findings were published in *Communications Physics*. Current clinical nuclear medicine PET examinations primarily utilize gamma rays generated from two-photon annihilation between positrons and electrons to visualize drug accumulation in the body. While this method provides quantitative information on metabolism or drug uptake, it offers limited insight into microenvironmental features such as tissue hypoxia, which are closely related to disease malignancy. In recent years, researchers have attempted to obtain additional tissue information through the average lifetime of positronium formed during positron annihilation, but this approach typically requires the introduction of special nuclides or agents, limiting its practical application.

2026-08-12

South Korea's Nuclear Energy Paper Output Ranks High but Quality Impact Remains Low

According to the report "Academic Competitiveness Analysis in Five Core and Emerging Technology Fields of the United States" released by the National Research Foundation of Korea on the 12th, from 2016 to 2025, South Korea's paper output in fields such as semiconductors, artificial intelligence, nuclear energy, biotechnology, and quantum information has maintained a certain level of competitiveness overall. Among these, the number of papers in the semiconductor field ranked 4th globally, artificial intelligence and nuclear energy both ranked 7th, biotechnology ranked 8th, and quantum information ranked 14th. The quantitative and qualitative status of South Korea in the five major fields. Excerpted from the National Research Foundation of Korea report. The report is based on analysis of data from SciVal, the research performance analysis platform of Elsevier. In terms of the share of South Korean papers in the global total...

2026-08-12

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

Fujita Health University in Japan Advances Research on Expanding BNCT Indications for Deep-Seated Cancers, to Conduct 18F-FBPA PET Exploratory Evaluation

On August 10, Stella Pharma Corporation of Japan announced that it is collaborating with Fujita Health University and other institutions to advance research and development aimed at expanding Boron Neutron Capture Therapy (BNCT) to deep-seated cancers. As part of this project, Stella Pharma will participate in an exploratory study on 18F-FBPA uptake capacity in deep-seated cancers conducted by Fujita Health University. The study will use 18F-FBPA PET to evaluate the tumor accumulation of boron drugs used in BNCT in deep-seated cancers, and based on the findings, explore the possibility of expanding BNCT indications in the future. The study plans to collect data from 50 cases, including pancreatic cancer, hepatocellular carcinoma, and biliary tract cancer, to accumulate foundational evidence needed for the development of BNCT for deep-seated cancers. BNC...

2026-08-11